Literature DB >> 2894889

Medical treatment of inflammatory bowel disease: new therapies, new drugs.

L R Sutherland1.   

Abstract

Ulcerative colitis, ulcerative proctitis and Crohn's disease are chronic inflammatory conditions that affect the gastrointestinal tract. Conventional treatment has stressed the role of anti-inflammatory agents to suppress the inflammatory response. New compounds that can deliver 5-aminosalicylic acid to the colon have recently been released in Canada. Metronidazole and azathioprine may also be of benefit in Crohn's disease. Therapy with cyclosporine and clonidine should be based on the results of further clinical trials. The use of nutritional support as primary therapy in Crohn's disease appears promising. At present, both pharmacologic and nutritional therapies should be considered in the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2894889      PMCID: PMC1267349     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  46 in total

1.  Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.

Authors:  S H Saverymuttu; S Gupta; A Keshavarzian; B Donovan; H J Hodgson
Journal:  Digestion       Date:  1986       Impact factor: 3.216

2.  Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; I P Cappello; C Corbelli; S Boschi
Journal:  Dis Colon Rectum       Date:  1986-02       Impact factor: 4.585

Review 3.  The role of arachidonic acid oxygenation products in pain and inflammation.

Authors:  P Davies; P J Bailey; M M Goldenberg; A W Ford-Hutchinson
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

Review 4.  Mediators of inflammation.

Authors:  G L Larsen; P M Henson
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

5.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J Rhodes; D Bainton; P Beck; H Campbell
Journal:  Lancet       Date:  1971-12-11       Impact factor: 79.321

6.  Studies of the antidiarrheal action of clonidine. Effects on motility and intestinal absorption.

Authors:  L R Schiller; C A Santa Ana; S G Morawski; J S Fordtran
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

7.  Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease.

Authors:  S Saverymuttu; H J Hodgson; V S Chadwick
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

8.  Retrograde spreading of hydrocortisone enema in inflammatory bowel disease.

Authors:  M Jay; G A Digenis; T S Foster; D R Antonow
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

Review 9.  Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?

Authors:  C J Hawkey; D S Rampton
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

10.  Olsalazine in active ulcerative colitis.

Authors:  W S Selby; G D Barr; A Ireland; C H Mason; D P Jewell
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.